Abdominal obesity, metabolic syndrome and respiratory function disturbance

1. Ametov A.S. Insulin secretion in normal and in type 2 diabetes mellitus. Sakharnyy diabet. 2007. (4). 11–16. (in Russian)
2. Ametov A.S. Obesity – an epidemic of the XXI century. Terapevticheskiy arkhiv. 2002. (10) 5–7. (in Russian)
3. Balabolkin M.I., Klebanova E.M., Kreminskaya V.M. Differential diagnosis and treatment of endocrine diseases: Manual. Moscow: Meditsina. 2002. 752 p. (in Russian)
4. Butrova S.A., Dzogoeva F.X. Visceral obesity – a key part of the metabolic syndrome. Ozhirenie i metabolism. 2004. (1). 10–16. (in Russian)
5. Voevoda M.I., Ragino Yu.I., Chernjavskii A.M. et al. The high prevalence of the metabolic syndrome in men with coronary atherosclerosis in Siberia Russian cardiological journal. 2010. (1). 65–70. (in Russian)
6. Kireev S.A. The clinical course, the parameters of systemic inflammation and lipid peroxidation in patients with COPD with metabolic syndrome according to body mass index: abstract of thesis … candidate of medical sciences. Moscow, 2011. (in Russian)
7. Kotovskaya Yu.V. Metabolic syndrome: prognostic significance and modern approaches to combination therapy. Serdtse. 2005. (23). 236–242. (in Russian)
8. Kravets E.B., Samoilova Yu.G., Matyusheva N.B. et al. Metabolic syndrome in general practice medicine. Byulleten' sibirskoy meditsiny. 2008. (1). 80–86. (in Russian)
9. Krasnoperova O.I., Smirnova E.N., Chistousova G.V. et al. Factors contributing to the formation of metabolic syndrome in children and adolescents. Ozhirenie i metabolism. 2013. (34). 18–21. (in Russian)
10. Nikitin Yu.P., Kazeka G.R., Simonova G.I. The prevalence of metabolic syndrome X in the urban population (epidemiological study) Kardiologiya. 2001. (9). 37–40. (in Russian)
11. The experts' recommendations of Russian Scientific Society of Cardiology for the diagnosis and treatment of metabolic syndrome: The second revision. Kardiovaskilyarnaya terapiya i profilaktika. 2009. (6, Suppl. 2). 1–29. (in Russian)
12. Shestakova M.V. Endothelial dysfunction – cause or consequence of metabolic syndrome? Russkiy meditsinskiy zhurnal. 2001. (2). 88–92. (in Russian)
13. Assmann G., Guerra R., Fox G. et al. Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations Am. J. Cardiol. 2007. 99. 541–548.
14. Cameron A. The metabolic syndrome: Validity and utility of clinical definitions for cardiovascular disease and diabetes risk prediction Maturitas. 2010. 65. (2). 117–121.
15. Cavailles A., Brinchault-Rabin G., Dixmier A. et al. Comorbidities of COPD Eur. Respir. Rev. 2013. 22. (130). 454–475.
16. Chen Y., Rennie D., Cormier Y.F., Dosman J. Waist circumference is associated with pulmonary function in normal-weight, overweight, and obese subjects Am. J. Clin. Nutr. 2007. 85. 35–39.
17. De Fronzo R.A., Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease Diabetes Care. 1991. 14. 173–194.
18. Despres J.-P., Lemieux I. Abdominal obesity and metabolic syndrome Nature. 2006. 444. 881–887.
19. Espinola-Klein C., Gori T., Blankenberg S. Inflammatory markers and cardiovascular risk in the metabolic syndrome Front. Biosci. 2011. 16. 1663–1674.
20. Faber D.R., van der Graaf Y., Westerink J., Visseren F.L. Increased visceral adipose tissue mass is associated with increased C-reactive protein in patients with manifest vascular diseases Atherosclerosis. 2010. 212. 274–280.
21. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey JAMA. 2002. 287. (3). 356–359.
22. Ford E.S., Mannino D.M. Prospective association between lung function and the incidence of diabetes: findings from the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study Diabetes Care. 2004. 27. 2966–2970.
23. Franssen F.M.E., O’Donnell D.E., Goossens G.H. et al. Obesity and the lung: Obesity and COPD Thorax. 2008. 63. (12). 1110–1117.
24. Furutate R., Ishii T., Wakabayashi R. Excessive visceral fat accumulation in advanced chronic obstructive pulmonary disease J. Chron. Obstruct. Pulmon. Dis. 2011. Vol. 6. 423–430.
25. Grundy S.M., Cleeman J.I., Daniels S.R. et al. Diagnosis and management of the metabolic syndrome: An American Heart Association / National Heart, Lung, and Blood Institute scientific statement Circulation. 2005. 112. (17). 2735–2752.
26. Guo S. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models to disease mechanisms J. Endocrinol. 2014. 220. (2). T1–T23.
27. Hossain P., Kawar B., Nahas M. Obesity and diabetes in the developing world a growing challenge N. Engl. J. Med. 2007. 356. (3). 213–215.
28. Hsiao F.C., Wu C.Z., Su S.C. Baseline forced expiratory volume in the first second as an independent predictor of development of the metabolic syndrome Metabolism. 2010. 59. (6). 848–853.
29. Kawada T. Insulin-related biomarkers to predict the risk of metabolic syndrome Int. J. Endocrinol. Metab. 2013. 11. (4). e10418.
30. Kwon C.H., Rhee E.J., Song J.U. et al. Reduced lung function is independently associated with increased risk of type 2 diabetes in Korean men Cardiovasc. Diabetol. 2012. 11. 38. PMCID PMC3464774.
31. Leon M.M., Stefanachi E., Cobzaru R. et al. Impact of metabolic syndrome on the development of cardiovascular disease Rev. Med. Chi. Soc. Med. Nat. Iasi. 2013. 117. (3). 635–640.
32. Leone N., Courbon D., Thomas F. et al. Lung function impairment and metabolic syndrome the critical role of abdominal obesity Am. J. Respir. Crit. Care Med. 2009. 179. (6). 509–516.
33. Lessmann E., Grochowy G., Weingarten L. et al. Insulin and insulin-like growth factor-1 promote mast cell survival via activation of the phosphatidylinositol-3-kinase pathway Exp. Hematol. 2006. 34. (11). 1532–1541.
34. Li H.L., Xu B., Zheng W. et al. Epidemiological characteristics of obesity and its relation to chronic diseases among middle aged and elderly men Zhonghua Liu Xing. Bing. Xue Za Zhi. 2010. 31. (4). 370–374.
35. Lorenzo C., SerranoRios M., Martinez-Larrad M.T. et al. Geographic variations of the International Diabetes Federation and the National Cholesterol Education Program-Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects Diabetes Care. 2006. 29. (3). 685–691.
36. Numata T., Araya J., Fujii S. et al. Insulin-dependent phosphatidylinositol 3-kinase/Akt and ERK signaling pathways inhibit TLR3-mediated human bronchial epithelial cell apoptosis J. Immunol. 2011. 187. (1). 510–519. 
37. Oda E., Kawai R. A cross-sectional relationship between vital capacity and metabolic syndrome and between vital capacity and diabetes in a sample Japanese population Environ. Health Prev. Med. 2009. 14. (5). 284–291.
38. Park B.H., Park M.S., Chang J. et al. Chronic obstructive pulmonary disease and metabolic syndrome: a nationwide survey in Korea Int. J. Tuberc. Lung Dis. 2012. 16. (5). 694–700.
39. Perez P.M., Moore-Carrasco R., Gonzalez D.R. et al. Gene expression of adipose tissue, endothelial cells and platelets in subjects with metabolic syndrome Mol. Med. Rep. 2012. 5. (5). 1135–1140.
40. Reaven G.M. Insulin resistance, compensatory hyperinsulinemia, essential hypertension and cardiovascular disease J. Clin. Endocrinol. Metab. 2003. 88. (6). 2399–2403.
41. Rinne S.T., Feemster L.C., Collins B.F. et al. Thiazolidinediones and the risk of asthma exacerbation among patients with diabetes: a cohort study Allergy Asthma Clin. Immunol. 2014. 10. (1). 34.
42. Rossi M., Matteucci E., Pesce M. et al. Peripheral microvascular dysfunction as an independent predictor of atherosclerotic damage in type 1 diabetes patients: a preliminary study Hemorheol. Microcirc. 2012. 54. (4). 381–391.
43. Salome C.M., King G.G., Berend N. Physiology of obesity and effects on lung function J. Appl. Physiol. 2010. 108. 206–211.
44. Schokker D.F., Visscher T.L.S., Nooyens A.S.J. et al. Prevalence of overweight and obesity in the Netherlands Obesity Rev. 2007. 8. (2). 101–108.
45. Shaaban R., Kony S., Driss F. et al. Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study Respir. Med. 2006. 100. 2112–2120.
46. Tamura Y., Kawao N., Yano M. et al. Plasminogen activator inhibitor-1 deficiency ameliorates insulin resistance and hyperlipidemia but not bone loss in obese female mice Endocrinology. 2014. 155. (5). 1708–1717.
47. The IDF consensus worldwide definition of the metabolic syndrome. Brussels, 2005. 16 p. http://www.idf.org/webdata/docs/MetS_def_update2006.pdf
48. Thijs W., Dehnavi R.A., Hiemstra P.S. et al. Association of lung function measurements and visceral fat in men with metabolic syndrome Respir. Med. 2014. 108. 351–357.
49. Wannamethee S.G., Shaper A.G., Rumley A. et al. Lung function and risk of type 2 diabetes and fatal and nonfatal major coronary heart disease events: possible associations with inflammation Diabetes Care. 2010. 33. (9). 1990–1996.
50. Weiss S.T., Shore S. Obesity and asthma: directions for research Am. J. Respir. Crit. Care. Med. 2004. 169. 963–968.
51. Yamamoto Y., Oya J., Nakagami T., Uchigata Y. Association between lung function and metabolic syndrome independent of insulin in Japanese men and women Jpn. Clin. Med. 2014. 5. 1–8.
52. Yang T., Chu C.H., Hsieh P.C. et al. C-reactive protein concentration as a significant correlate for metabolic syndrome: a Chinese population-based study Endocrine. 2013. 43. 351–359.
53. Yeh H.C., Punjabi N.M., Wang N.Y. et al. Vital capacity as a predictor of incident type 2 diabetes: the Atherosclerosis Risk in Communities study Diabetes Care. 2005. 28. (6). 1472–1429.
54. Zimmet P., Shaw G., Alberti G. Type 2 diabetes and the dysmetabolic syndrome in the real word: a realistic view Diabet. Med. 2003. 20. (9). 693–702.

Travnikova N.Yu. – post graduate student, e-mail: shkutka@yandex.ru

Ragino Yu.I. – doctor of medical sciences, professor, head of laboratory of biochemical and hormonal investigations of therapeutic diseases, e-mail: ragino@mail.ru

Kovalkova N.A. – candidate of medical sciences, researcher of laboratory of biochemical and hormonal investigations of therapeutic diseases, e-mail: terap2000@yandex.ru

Voevoda M.I. – doctor of medical sciences, professor, corresponding member of RAS, director, e-mail: mvoevoda@ya.ru